BlossomHill Therapeutics Sets $150M IPO at $16.00 a Share
Summary
BlossomHill Therapeutics priced its IPO at $16.00 per share, raising $150 million to fund clinical development of its cancer drug candidates.
Key Events · Financing and Capital Events · BLSM
-
IPO Pricing
The offering consists of 9,375,000 shares priced at $16.00 each, yielding $150 million in gross proceeds.
-
Use of Proceeds
After underwriting fees, net proceeds of approximately $134.9 million will fund clinical development of BH-30643, BH-30236, and BH-501284, extending the cash runway into early 2028.
-
Nasdaq Listing
The shares have been approved for listing on the Nasdaq Global Select Market under the symbol 'BLSM,' with trading expected to begin on August 10, 2026.
-
Underwriters
J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, and H.C. Wainwright & Co. are serving as underwriters for the offering.
Analysis · BLSM · Life Sciences
BlossomHill Therapeutics has locked in the terms of its initial public offering, pricing 9.375 million shares at $16.00 apiece to generate $150 million in gross proceeds. The deal implies a post-money valuation of roughly $490 million and secures vital funding to advance its oncology pipeline, led by BH-30643 for EGFR-mutant non-small cell lung cancer. For the clinical-stage biotech, this milestone extends the cash runway into early 2028 and opens a path toward a potential accelerated approval. Pricing at the midpoint of the expected range signals solid institutional demand, though existing shareholders will feel a notable dilutive impact.
At the time of this filing, BLSM was trading at $16.00 on NASDAQ in the Life Sciences sector. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.